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Abstract 
 
Genome-wide association analysis advanced understanding of blood pressure (BP), a major risk 
factor for vascular conditions such as coronary heart disease and stroke. Accounting for smoking 
behavior may help identify novel BP loci and extend our knowledge of its genetic architecture. 
We performed genome-wide association meta-analyses of systolic and diastolic BP incorporating 
gene-smoking interactions in 610,091 individuals. Stage 1 analysis examined ~18.8 million 
SNPs and small insertion/deletion variants in 129,913 individuals from four ancestries 
(European, African, Asian, and Hispanic) with follow-up analysis of promising variants in 
480,178 additional individuals from five ancestries. We identified 15 new loci that were genome-
wide significant (P < 5×10-8) in Stage 1 and formally replicated in Stage 2. A combined Stage 1 
and 2 meta-analysis identified 66 additional genome-wide significant loci (13, 35, and 18 loci in 
European, African and trans-ancestry, respectively). A total of 56 known BP loci were also 
identified by our results (P < 5×10-8). Of the newly identified loci, 10 showed significant 
interaction with smoking status, but none of them were replicated in Stage 2. Several loci were 
identified in African ancestry, highlighting the importance of genetic studies in diverse 
populations. The identified loci show strong evidence for regulatory features and support shared 
pathophysiology with cardiometabolic and addiction traits. They also highlight a role in BP 
regulation for biological candidates such as modulators of vascular structure and function 
(CDKN1B, BCAR1-CFDP1, PXDN, EEA1), ciliopathies (SDCCAG8, RPGRIP1L), telomere 
maintenance (TNKS, PINX1, AKTIP), and central dopaminergic signaling (MSRA, EBF2). 
Words: 245 (250 words max in AJHG)  
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Introduction 
 
The management of blood pressure (BP) is a major public health priority with implications for 
the prevention of coronary heart disease, heart failure, stroke, and other vascular conditions. BP 
is partly under genetic control with moderately high heritability (30-60%),1 although only a small 
fraction of the heritability has been explained by variants identified through genome-wide 
association studies (GWAS).2 Specifically, the common variants initially identified through three 
collaborative consortia for genome-wide BP genetics in people of European ancestry1; 3; 4 explain 
less than 2.5% of the variance in systolic BP (SBP) or diastolic BP (DBP).4 Recent reports based 
on larger sample sizes have increased the number of BP associated variants which together 
explain about 3.5% of BP variance.5-7 In contrast, only six BP loci have been identified by 
GWAS in African ancestry which explain less than 0.54% of BP variance.8; 9 A focus on main 
effects to the exclusion of interactions in these studies may have limited the discovery of a full 
complement of genetic influences on BP. In particular, incorporating interactions between 
genetic variants and environmental exposures (GxE) represents a novel additional route for 
discovery of genetic effects on complex traits,10 including BP, and may more generally extend 
our knowledge of the genetic architecture of complex traits.11  
 
Many lifestyle factors including physical activity, tobacco use, alcohol consumption, stress, and 
dietary factors influence BP.12 These lifestyle exposures may also modify the effect of genetic 
variants on BP. Cigarette smoking is known to influence BP in both acute13 and chronic14; 15 
fashion, motivating genetic association studies accounting for potential gene-by-smoking 
interactions. This may help identify novel BP loci, and such BP loci driven by GxE interactions 
may reveal new biological insights and mechanisms that can be explored for treatment or 
prevention of hypertension.  
 
The recently established Gene-Lifestyle Interactions Working Group within the Cohorts for 
Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium has designed a 
series of multi-ancestry genome-wide interaction projects focused on assessing the impact of 
interactions with multiple lifestyle factors on the genetics of cardiovascular traits.16 The primary 
goal of these investigations is to use interactions to identify novel trait loci that act 
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synergistically with lifestyle factors. Large scale interaction studies like this one represent “an 
important milestone on the path toward a far more complete understanding of the origins of 
cardiovascular disease and a better understanding of how to manage it”.17 Within this setting, we 
performed a genome-wide association meta-analysis incorporating gene-smoking interactions 
(overview shown in Figure 1) to identify novel SBP and DBP loci and understand the 
modulating role of cigarette smoking in the genetic architecture of BP. Here we report our 
findings based on a total of 610,091 individuals from five ancestry groups which provide 
adequate power for discovery.16 
Methods 
Overview of participating studies 
Men and women between the ages of 18-80 years from five self-reported ancestry groups are 
represented in this study: European (EUR), African (AFR), Asian (ASN), Hispanic (HIS), and 
Brazilian admixed (BRA). These participating studies are described in the Supplemental Notes. 
Each study obtained informed consent from participants and approval from the appropriate 
institutional review boards. Although the participating studies are based on different study 
designs and populations, all of them have data on BP, smoking, and genotypes across the 
genome (data imputed using the 1000 Genomes reference panel in most cohorts). In total, this 
study involves two stages comprising 610,091 individuals. 
A total of 48 cohorts participated in Stage 1 and performed genome-wide interaction analyses 
(Table S1). This stage included 80,552 EUR, 27,118 AFR, 13,438 ASN, and 8,805 HIS for an 
overall total of 129,913 individuals. A total of 76 cohorts participated in Stage 2 and performed 
analyses of 4,459 variants that were identified in Stage 1 as either genome-wide significant (P < 
5×10-8) or suggestive (P < 10-6) for any of the BP-smoking combinations for either 1 DF or 2 DF 
tests (Table S2). This stage included 305,513 EUR, 7,786 AFR, 148,932 ASN, 13,533 HIS, and 
4,414 Brazilian Admixed (BRA) individuals to a total of 480,178 individuals in Stage 2. Since 
discoveries to date are largely from EUR populations, we optimized the chances of novel 
discovery in non-EUR populations (especially in AFR) by recruiting most of the available non-
EUR cohorts into Stage 1. 
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Phenotypes and Lifestyle Variables 
The two BP traits were analyzed separately: resting SBP (mmHg) and DBP (mmHg). For 
individuals taking any anti-hypertensive (BP lowering) medications, their SBP and DBP values 
were first adjusted for medication effects by adding 15 mmHg to SBP and adding 10 mmHg to 
DBP.3 Summary statistics are shown in Table 1 (more details in Tables S3-S4). These 
medication-adjusted BP variables were approximately normally distributed, as shown in Table 
S5 and Figure S1. In addition, to reduce the influence of possible outliers, winsorizing has been 
applied for each BP value that was more than 6 standard deviations away from the mean.  
The participating cohorts have varying levels of information on smoking, some with a simple 
binary variable and others (such as UK Biobank) with more precise data. We considered two 
dichotomized smoking variables ‘current smoking’ status (CurSmk) and ‘ever smoking’ status 
(EverSmk), as they were the most widely available information (Table 1). Current smoking 
status was coded as 1 if the subject smoked regularly in past year (and as 0 for non-current 
smokers which includes both never and former smokers). Ever smoking status was coded as 1 if 
the subject smoked at least 100 cigarettes during his/her lifetime (and as 0 for the never-
smokers). Smoking status was assessed at the time of the BP measurements. When subjects have 
the multiple smoking measures that were inconsistent, they were excluded from analysis. 
Subjects with missing data for BP, the smoking variable, or any covariates were excluded from 
analysis. 
Genotype Data 
 
Genotyping was performed using Illumina (San Diego, CA, USA) or Affymetrix (Santa Clara, 
CA, USA) genotyping arrays. Each study performed imputation to impute genotypes for single 
nucleotide polymorphisms (SNPs), short insertions and deletions (indels), and larger deletions 
that were not genotyped directly but are available from the 1000 Genomes Project.18 Information 
on genotype and imputation for each study is presented in Tables S6-S7. For imputation, most 
studies used the 1000 Genomes Project Phase I Integrated Release Version 3 Haplotypes (2010-
11 data freeze, 2012-03-14 haplotypes), which contain haplotypes of 1,092 individuals of all 
ethnic backgrounds.  
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Cohort-specific GWAS Analysis 
 
For SBP and DBP separately, each study performed association analyses accounting for two 
smoking exposure variables, current smoking (CurSmk) and ever smoking (EverSmk). In Stage 
1, we considered two models to account for gene-smoking interactions. For the first ‘joint’ 
model, a regression model including both genetic main and GxE interaction effects  
𝔼𝔼[𝑌𝑌|𝐺𝐺,𝐶𝐶] =  𝛽𝛽0 +  𝛽𝛽𝐸𝐸𝑆𝑆𝑆𝑆𝑆𝑆 +  𝛽𝛽𝐺𝐺𝐺𝐺 +  𝛽𝛽𝐺𝐺𝐸𝐸𝑆𝑆𝑆𝑆𝑆𝑆 ∗ 𝐺𝐺 + 𝜷𝜷𝑪𝑪𝑪𝑪 
was applied to the entire sample. For the second ‘stratified’ model, analyses of the genetic main-
effect regression models  
𝔼𝔼[𝑌𝑌|𝐶𝐶, 𝑆𝑆𝑆𝑆𝑆𝑆 = 0] =  𝛾𝛾0(0) + γ𝐺𝐺(0)𝐺𝐺 + 𝛄𝛄𝑪𝑪(𝟎𝟎)𝑪𝑪 
𝔼𝔼[𝑌𝑌|𝐶𝐶, 𝑆𝑆𝑆𝑆𝑆𝑆 = 1] = 𝛾𝛾0(1) + γ𝐺𝐺(1)𝐺𝐺 + 𝛄𝛄𝑪𝑪(𝟏𝟏)𝑪𝑪 
were applied separately to the Smk = 0 unexposed group and to the Smk = 1 exposed group 
(smokers). Y is the medication-adjusted BP value, Smk is the smoking variable (with 0/1 coding 
for the absence/presence of the smoking exposure), G is the dosage of the imputed genetic 
variant coded additively (from 0 to 2), and C is the vector of all other covariates, which include 
age, sex, field center (for multi-center studies), and principal component (PC)s (to account for 
population stratification and admixture). No additional cohort-specific covariates  were included. 
Our previous work showed that the two (joint and stratified) models provided highly similar 
inference.19 Therefore, we considered only the first ‘joint’ model in Stage 2. 
 
Each study in Stage 1 performed GWAS analysis within each ancestry and provided a) the 
estimated genetic main effect βG, estimated interaction effect βGE and a robust estimate of the 
corresponding covariance matrix under the joint model; and b) estimates of the stratum-specific 
effects 𝛾𝛾𝐺𝐺
(0), 𝛾𝛾𝐺𝐺(1) and robust estimates of their standard errors (SE) under the stratified model. 
Each study in Stage 2 provided estimates of the genetic main effect βG, the interaction effect βGE 
and robust estimates of the corresponding covariance matrix under the joint model at 6,370 select 
variants. Robust estimates of covariance matrices and SEs were used to safeguard against both 
mis-specification of the mean model and violation of the assumption of constant BP variance 
across smoking groups (heteroscedasticity).20; 21 Association analysis was performed using 
various software (Tables S6-S7). To obtain robust estimates of covariance matrices and robust 
SEs, studies of unrelated subjects used either the R package sandwich22 or ProbABEL.23 To 
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account for relatedness in families, family studies used the generalized estimating equations 
(GEE) approach, treating each family as a cluster, or the linear mixed effect model approach 
with a random polygenic component (for which the covariance matrix depends on the kinship 
matrix). 
Quality control 
 
Study investigators participating in this study have ample experience in main-effect based 
GWAS for multiple phenotypes and are very familiar with validated approaches for quality 
control (QC) of phenotype, genotype, and imputed data. For example, cohort level analyses used 
PCs as covariates to deal with population structure; family studies used suitable software 
packages to deal with relatedness (Table S6). Overlap among some of the participating cohorts is 
a potential possibility. However, when there was known overlap of samples across cohorts, one 
of the cohorts used a non-overlapping sub-sample for their analysis.  
 
We performed extensive QC using the R package EasyQC24 for all cohort-specific GWAS 
results. In Stage 1, each cohort provided 12 GWAS result files (2 BPs x 2 Smoking exposures x 
3 analyses, 1 for model 1 and 2 for model 2) for each ancestry group. Each GWAS result file 
included approximately 8-15 million high-quality variants (depending on ancestry), as cohorts 
applied a preliminary filter on their imputed data excluding variants with minor allele frequency 
(MAF) < 1% or imputation quality measure < 0.1. We performed two QC levels: “study-level” 
and “meta-level”. To identify problems with population substructures or relatedness, we have 
examined QQ plots and genomic control inflation factors (lambdas) on a study-by-study level (to 
identify study-specific issues) as well as on the meta-analysis result (to identify cross-study 
issues). Because GWAS were performed within each ancestry, the “study-level” QC also 
carefully checked the provided allele frequencies against the retrospective ancestry-specific 1000 
genomes reference panel. Finally, marker names were harmonized to ensure consistencies across 
cohorts. In addition, we contrasted results from the joint model and stratified models in Stage 1 
cohorts, as explained elsewhere.19 The “meta-level” QC reviewed result files of a specific 
analysis (e.g., SBP-CurSmk-Model1) across all cohorts: this included 1) visually comparing 
summary statistics (mean, median, standard deviation, inter-quartile range, minimum, maximum) 
on all effect estimates standard errors (SEs) and p-values; and 2) examining SE-N and QQ plots 
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to reveal issues with trait transformation24 or other analytical problems. Any problems found 
during QC steps, including major differences from the ancestry-specific reference panel and any 
inflation of lambdas within studies, were communicated and resolved with the individual 
cohorts. Similar QC steps were applied to cohort-specific results in Stage 2. More detailed 
information about the QC steps, including major QC problems encountered and how they were 
resolved, are described elsewhere.16 
 
The most crucial filter during the meta-analysis was approximate DF = min (MAC0, MAC1) * 
imputation quality measure; this is based on the minor allele count (MAC) in each stratum 
(MAC0 and MAC1) and imputation quality measure, where MAC0 = 2 * MAFE0 * NE0 for the 
unexposed group (with MAFE0 and sample size NE0 for E=0 stratum) and MAC1 = 2 * MAFE1 * 
NE1 for the exposed group. In meta-analysis, to exclude unstable cohort-specific results that 
reflect small sample size, low MAF, or low imputation quality measures, variants were excluded 
if approximate DF < 20. This filtering threshold was decided after considering various thresholds 
and examining the resulting QQ and Manhattan plots. More details are provided in Supplemental 
Notes. Variants were further excluded if imputation quality measure < 0.5.  This value of 0.5 was 
used regardless of the software used for imputation, because imputation quality measures are 
shown to be similar across imputation software.25  
Meta-analysis 
 
After conducting extensive quality control and selecting high-quality variants, approximately 
18.8 million SNPs and small insertion and deletion (indels) variants were included in the meta-
analysis (the number of variants varied across the ancestry groups). We performed meta-analysis 
using both models in Stage 1 and using the joint model in Stage 2. For both stages, we performed 
meta-analysis using the 1 degree of freedom (DF) test of interaction effect and 2 DF tests of 
testing both SNP main and interaction effects. Wald test statistics approximately follow either a 
chi-squared distribution with 1 DF under H0: βGE = 0 for the 1 DF test or  a chi-squared 
distribution with 2 DF under H0: βG = βGE = 0, for the 2 DF test. In the joint model, inverse-
variance weighted meta-analysis was performed for the 1 DF test and the joint meta-analysis of 
Manning et al26 for the 2 DF test, both using METAL.27 In the stratified model, we performed 
meta-analysis using the approach of Randall et al28 for the 1 DF test and the approach of Aschard 
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et al29 for the 2 DF test. Both tests in the stratified model were computed using the R package 
EasyStrata.30 More details are described elsewhere.19  
 
Ancestry-specific meta-analyses using inverse-variance weighting were performed to combine 
cohort-specific results within each ancestry. The ancestry-specific results were then combined 
through meta-analysis to obtain  evidence of “trans-ancestry” association. In Stage 1, 80 separate 
genome-wide meta-analyses were performed: 2 BPs x 2 smoking exposures x 4 (2 tests in the 
joint model, 2 stratified groups in the stratified model) x 5 ancestries (4 ancestry-specific and one 
trans-ancestry to combine ancestry-specific results). In this stage, genomic control correction31 
was applied twice, first for cohort-specific GWAS results if their genomic control lambda value 
was greater than 1, and again after the meta-analysis results. Variants were excluded if they were 
represented by valid data in fewer than 5,000 samples and 3 cohorts. Variants that were genome-
wide significant (P < 5×10-8) or suggestive (P < 1×10-6) in any of Stage 1 analyses were pursued 
for Stage 2 analysis. In Stage 2, 48 separate meta-analyses were performed using the joint model: 
2 BPs x 2 smoking exposures x 2 (2 tests; 1 DF and 2 DF tests) x 6 ancestries (5 ancestry-
specific and one trans-ancestry to combine ancestry-specific results). Genomic control correction 
was not applied to the replication statistics as association analysis was performed only at select 
variants. Similarly, 48 separate meta-analyses were performed to combine Stages 1 and 2 results.  
Genome-wide Significant Variants 
If a variant reached genome-wide significance (P < 5×10-8) through any of these 48 combined 
association meta-analyses (which are not independent), then the variant was considered as 
genome-wide significant. To identify a set of independent (index) variants through ancestry-
specific and trans-ancestry analysis, we performed the linkage disequilibrium (LD)-based 
clumping procedure using PLINK32 and EasyStrata.30 A locus is defined through LD-based 
clumping that uses both physical distance (± 1 Mb) and LD threshold of r2 > 0.1. Since valid 
methods do not exist for conditional analysis involving interactions across multi-ancestry studies, 
we relied on a relatively more stringent LD threshold (r2 > 0.1) for identifying “independent” 
loci. As LD reference, ancestry-specific 1000 Genomes Project data were used for ancestry-
specific results and the entire cosmopolitan dataset was used for trans-ancestry results. False 
discovery rate (FDR) q-values were computed using the R function p.adjust using the step-up 
method by Benjamini and Hochberg.33 
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BP variance explained 
Since variants weakly correlated with index variants (0.1 ≤  r2 ≤ 0.2) can contribute to the 
percent variance, for the purposes of calculating percent variance, we carried out clumping using 
slightly less conservative LD threshold (r2 > 0.2 instead of > 0.1). The percent of variance 
explained in SBP and DBP by all previously known (158) and newly identified variants (132 
using LD threshold of >0.2 for clumping) was evaluated in several studies from multiple 
ancestries (see Table S8). BP variants previously identified in any ancestry were considered as 
‘known’ variants. Similarly, we considered all index variants representing newly identified loci 
as novel for this purpose regardless of which ancestry they were identified in; separate 
interaction terms were included for newly identified variants. Known and newly identified 
variants (combined from all ancestries) were used in assessing the percent variance. 
Percent variance was calculated using standard regression models. Four nested models were 
considered. The first model included the smoking variables and standard covariates (age, sex, 
PCs, etc.); the second model included those covariates and all known variants; the third model 
contained all those previous variables and all newly identified variants (excluding any interaction 
terms); finally, the fourth model contained all those (covariates, known, and novel) plus the 
interaction terms. Each of SBP and DBP was regressed on the relevant predictors in each of the 4 
models. The r2 values obtained from the regressions were used as measures of the percent 
variance explained by the respective models. Through sequential subtraction of appropriate r2 
values, we determined the “additional” percent variance explained by a given set of variants. For 
studies with N < 20,000, we used a stepwise regression procedure with significance tests for 
inclusion of one variant at a time and for backward elimination of redundant variants. 
Functional inference 
Variant Effect Predictor (VEP) from Ensembl was used to obtain the gene name for each locus. 
For the variants whose gene names were not identified by VEP, NCBI SNP database was used to 
obtain the closest gene. We applied several computational strategies to infer biological functions 
associated with our newly identified loci. We used HaploReg, RegulomeDB, and GTEx34 to 
obtain annotations of the noncoding genome, chromatin state and protein binding annotation 
from the Roadmap Epigenomics and ENCODE projects, sequence conservation across 
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mammals, and the effect of SNPs on expression from eQTL studies. To further assess putative 
functionality for the new loci, we searched for cis associations between new variants and gene 
transcripts using previously published eQTL analyses, which includes the GTEx.34  
Further eQTL evidence was queried using the eQTL database of Joehanes et al.35 for transcripts 
associated in both cis and trans in over 5,000 individuals from the Framingham Heart Study, 
with genome-wide false discovery rate (FDR) < 0.05. Two Gene-Set Enrichment Analysis 
(GSEA) queries were then performed on December 23, 2016 to determine the enrichment of 
biological processes and disease pathways of the resulting transcripts. Prior to the queries, 
duplicated gene names and genes with provisional names (such as LOCXXX) were first 
removed. Then, for each transcript probe associated with more than one gene name, only the first 
gene name was taken. This process yielded 127 gene names for the GSEA query. For querying 
biological processes, option C5:BP was selected on the GSEA website. For querying disease 
pathway, option C2:CP was selected. Both GSEA queries were set at FDR < 0.05 threshold to 
guard against multiple comparison errors. 
Pathway and gene set enrichment analysis 
 
We conducted four separate DEPICT analyses based on the following criteria that were applied 
to our combined association meta-analysis results. We utilized variants showing genome-wide 
significant joint effect association with 1) SBP in Europeans (PEUR.SBP < 5×10-8), 2) DBP in 
Europeans (PEUR.DBP < 5×10-8), 3) SBP in trans-ancestry analysis (PTrans.SBP < 5×10-8) or 4) DBP 
in trans-ancestry analysis (PTrans.DBP < 5×10-8). For each combination, DEPICT first performed 
the following steps to obtain the input of the prioritization and enrichment analyses: non-
overlapping regions lists of independent variants were obtained using 500 kb flanking regions 
and LD r² > 0.1 using the 1000 Genomes data,18 resulting variants were merged with overlapping 
genes (r² > 0.5 with a functional coding variant within the gene or cis-acting regulatory variant), 
and the major histocompatibility complex region on chromosome 6 (base position 25,000,000 - 
35,000,000) was excluded.  
 
DEPICT prioritized genes at the associated loci based on their functional similarity. Functional 
similarity of genes across associated loci was quantified by computing a gene score that was 
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adjusted for bias through confounders such as gene length. Experiment-wide FDR for the gene 
prioritization was obtained by repeating the scoring step 50 times based on lead variants from 
500 pre-compiled null GWAS. For the gene-set enrichment analyses, DEPICT utilized a total of 
14,461 pre-compiled reconstituted gene sets comprising 737 Reactome database pathways, 2,473 
phenotypic gene sets (derived from the Mouse Genetics Initiative), 184 Kyoto Encyclopedia of 
Genes and Genomes (KEGG) database pathways, 5,083 Gene Ontology database terms, and 
5,984 protein molecular pathways (derived from protein-protein interactions). For the tissue and 
cell type enrichment analyses, DEPICT tested whether genes harboring associated loci are 
enriched for expression in any of the 209 MeSH annotations for 37,427 microarrays of the 
Affymetrix U133 Plus 2.0 Array platform.  
 
To further identify connected gene sets and pathways implicated by our findings, we performed 
GeneGO analysis and text data mining using Literature Lab.36 GeneGO (known also as 
MetaCore) evaluates p-values for pathways by mapping a list of target genes to each pathway 
and comparing those that arise by chance using a hypergeometric distribution formula.  GeneGO 
implements a correction of p-values using a false discovery rate. Literature Lab of Acumenta 
evaluates co-occurrences in the publication records of a list of genes and biological and 
biochemical terms. The analysis compares the gene input set against the average of 1,000 
randomly generated similar size sets, providing a spectrum of statistically significant 
associations. Our Literature Lab analysis included the use of 17,261,987 PubMed abstracts, out 
of which 10,091,778 abstracts include one or more human genes.  
Results 
Study overview 
We performed the traditional 2-step approach with discovery in Stage 1 followed by formal 
replication in Stage 2. Because this study was not optimally designed for replications in non-
EUR (especially in AFR) ancestry, to identify additional loci, we performed combined analysis 
of stages 1 and 2 to maximize power for discovery37 (Figure 1). For the 2-step approach, we 
performed ancestry-specific meta-analysis in each of 5 ancestries and trans-ancestry analysis in 
Stage 2. We checked whether each of the genome-wide significant loci in Stage 1 was replicated 
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in Stage 2 using Bonferroni-adjusted significance level (0.05/74, see details below). For the 
combined analysis, we performed ancestry-specific meta-analysis combining both Stages 1 and 2 
(discovery and follow-up) in each of 5 ancestries; these ancestry-specific meta-analyses results 
were then combined to perform trans-ancestry analysis at 4,459 variants using a total of up to 
610,091 individuals.  
Two-step approach of discovery followed by replication 
 
Of the 4,459 significant or suggestive variants selected from Stage 1 meta-analyses, 3,222 were 
replicated in Stage 2 with P < 0.05/4,459 (to an aggregate replication rate of 72.3%). Of the 
1,993 variants that were genome-wide significant (P < 5×10-8) in Stage 1 analysis, 1,836 were 
replicated in Stage 2 with P < 0.05/1,993 to a replication rate of 92.1%. These 1,993 genome-
wide significant variants in Stage 1 belong to 114 independent loci . Of the 114 loci, 40 loci 
(consisting of 1,644 variants) contain previously published BP variants.1; 3-7 Of the remaining 74 
newly identified loci (consisting of 349 variants), 15 loci were formally replicated in Stage 2 
using Bonferroni-adjusted significance level (P < 0.05/74) (Table 2); all 15 novel loci were 
replicated even when using the more conservative adjustment threshold P < 0.05/349. In 
addition, 25 more of the remaining 59 loci were nominally replicated (P < 0.05) in one or more 
of the analyses in Stage 2 (P < 0.05), and 27 more showed the same direction of effect in Stages 
1 and 2. For 7 loci, no additional data were available in Stage 2 and, therefore, it was not 
possible to check for replication.  For the 15 formally replicated loci, estimates of the genetic 
main effects were all consistent between Stage 1 and 2; estimates of SNP-smoking interaction 
effects were not statistically significant (forest plots;  Figure S3). All of the 15 replicated loci 
were genome-wide significant in European ancestry. Furthermore, 10 loci also had supporting 
evidence from non-European ancestry, resulting in stronger statistical significance from trans-
ancestry analysis (Figure S3, Table 2). Quantile-quantile (QQ) plots for the genome-wide Stage 
1 meta-analysis are shown in Figure S2.  
 
Of the 15 formally replicated loci, six loci (indicated by f in Table 2) are completely novel, at 
least 1MB away from any previously published BP variants. Three of them (near PRAG1, 
MIR124-1, and FTO) show compelling biological relevance (see below) and eQTL evidence 
(Figure 2). The locus zoom plots of all newly identified loci identified in this paper are shown in 
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Figure S4. The remaining 9 loci are novel signals (which meet our definition of a locus) near but 
not in LD (r2 < 0.1) with known BP loci. For example, near the well-known BP locus ATP2B1 on 
chromosome 12, there were 2 independent signals identified in European (P = 4.1×10-41), Asian 
(P = 1.5×10-13), and trans-ancestry (P = 2.5×10-54) analyses. Near another well-known BP locus 
MTHFR-NPPB-CLCN6, we identified 3 additional independent signals (with p-values as small 
as 4.3×10-34 at index variants, spanning 196kb [from 11,827,796 to 12,023,500] on chromosome 
1).   
Combined analysis of Stages 1 and 2 
 
Combined meta-analysis of Stages 1 and 2 identified a total of 82 additional independent loci (P 
< 5 × 10-8) not identified by the 2-step approach. Association statistics for all genome-wide 
significant variants in the combined meta-analysis are provided in Table S9. Manhattan plots of 
the combined meta-analysis for each BP trait using the 1 DF interaction and 2 DF joint tests are 
shown in Figures S5-S8. Summary Manhattan plots for SBP and DBP with the minimum p-
values across all analyses are shown in Figure S9. QQ plots are shown in Figure S10. 
 
Of these 82 additional loci identified through combined analysis, 16 loci contain previously 
published BP variants.1; 3-7 All of the remaining 66 loci had a low false discovery rate (FDR 
q value < 0.1 for all 66 loci and < 0.01 for 60 of the loci, Table S10). Of these 66 loci, 18 and 13 
loci were identified through trans-ancestry (Table 3) and European-ancestry (Table 4), 
respectively. Except for one locus, they were suggestive (P < 1×10-6) in Stage 1 analyses but 
became significant in the combined Stages 1 and 2 meta-analysis (Tables 3-5). The strength of 
the combined analysis was exemplified by a locus in HOTTIP on chromosome 7 (locus 4 in 
Table 3), which were suggestive in Stage 1 analysis (P = 9.4×10-7) and identified through the 
combined analysis in European (P = 6.0×10-29), Asian (P = 1.2×10-10), and trans-ancestry (P = 
3.6×10-41, see Figure S3). Genome-wide significant loci from trans-ancestry analysis did not 
show strong evidence of heterogeneity across ancestry groups. 
 
Of the 66 identified loci, 35 were found through African-ancestry only (Table 5). These loci 
were mostly low-frequency with MAF between 1% and 5% (Table 5). Of these 35 loci, 4 were 
genome-wide significant in Stage 1 African ancestry and stayed significant in the combined 
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analysis (although not formally replicated in Stage 2). One such locus was near BMP7 on 
chromosome 20 (with P = 5.8×10-10 in Stage 1; P = 0.03 in Stage 2; P = 4.2×10-12 in Stage 1+2). 
Six loci were suggestive (P < 1×10-6) in Stage 1 analyses but became significant in the combined 
Stages 1 and 2 meta-analysis. One such locus was near WSCD1 on chromosome 17 (with P = 
8.7×10-7 in Stage 1; P = 0.00047 in Stage 2; P = 1.8×10-10 in Stage 1+2). The remaining 25 loci 
were genome-wide significant in Stage 1 African ancestry but not represented in Stage 2 African 
ancestry due to limited sample sizes and low MAF. Furthermore, 15 loci were African-specific 
loci; they had MAF < 1% in the other ancestry groups and were filtered out by the individual 
studies (by design), and therefore results are unavailable for further analysis. In the non-AFR 
ancestry results, genome-wide significant variants at newly identified loci were mostly common 
(with MAF ≥ 5%) and had similar MAF distributions as those at known loci (Figure S10).  
Known BP loci 
 
At most of the 56 known BP loci1; 3-7 identified in the two-step or combined analyses, the lead 
variant identified by our analyses was the same as the one previously published (Table S11); 
European-, Asian-, and trans-ancestry results identified 48, 14, and 50 of these variants, 
respectively. In the remaining loci, our results identified a variant in the same locus as the known 
BP variant. The most significant results were observed at well-known BP loci: ATP2B1 
(rs17249754 on chromosome 12, trans-ancestry PSBP = 4.8×10-85; PDBP = 5.5×10-57) and SH2B3-
ATXN2 (rs3184504 on chromosome 12, trans-ancestry PSBP = 3.2×10-36; PDBP = 6.0×10-67).  
The role of interactions 
 
Interaction effects contributed in varying degrees to the evidence of association for the 81 newly 
reported genome-wide significant loci (Tables 2-5). The genetic effects of these new index 
variants (each index variant representing a locus with the smallest p-value) were different in 
smokers and non-smokers, thus highlighting the potentially important role of interactions 
(Figure 3). Among the 81 index variants, 10 variants showed genome-wide significant 
interactions with smoking exposure status (1 DF interaction P < 5×10-8). All 10 of these variants, 
most of which were identified in African ancestry, show larger effects on BP in smokers (Figure 
3). However, none of the interactions were replicated in stage 2. In addition, of the 158 
previously reported BP variants, two (rs3752728 in PDE3A and rs3184504 in SH2B3-ATXN2) 
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show significant evidence of interactions with smoking using Bonferroni correction (1DF 
interaction P < 0.05/158). Twenty seven additional variants show nominal evidence of 
interaction (with P < 0.05). 
 
To minimize spurious results, we winsorized extreme BP values and used robust standard errors 
in cohort-specific analyses. Moreover, since non-normality and unequal BP variances among 
smokers and non-smokers can lead to false positives, we examined these characteristics in three 
large studies (ARIC, UK Biobank, and WGHS). The distributions look very similar in exposed 
and unexposed groups (histograms in Figure S1). The variances across strata are also very 
similar (Table S5). Moreover, on average across all Stage 1 cohorts, skewness is 0.64 for SBP 
and 0.36 for DBP; kurtosis is 3.52 for SBP and 3.32 for DBP (Table S3). There do not seem to 
be substantial deviations from normality although moderate deviations exist. , Therefore, it is 
less likely that the interaction effects at these 10 newly identified loci are spurious.  
BP variance explained  
 
In several large cohorts, we calculated the percent of BP variance explained by various loci 
across four ancestries (Table S8). The variance explained by the 158 previously known loci 
ranges from 1.1% (in HIS) to 3.2% (in EUR) for SBP and ranges from 1.6% (in ASN & HIS) to 
3.4% (in AFR) for DBP. The additional variance explained by the  newly identified loci and their 
interactions ranges from 0.6% (in EUR) to 2.6% (in AFR) for SBP and ranges from 0.3% (in 
ASN) to 3.2% (in AFR) for DBP. The percent variance explained is ideally calculated in large 
individual studies which did not participate in our analysis in Stage 1 or 2. However, having 
recruited most of the studies available to us into Stage 1 or 2 (for maximizing power), we had to 
use some of the same studies for this purpose and therefore some of the variance estimates may 
be somewhat inflated. In an independent EUR study (Airwave study, N=14,002) which did not 
participate in Stage 1 or 2, known variants explained 1.6% of variance in SBP and DBP, and 
newly identified variants and their interactions explained 1.2% variance in SBP and 1.3% 
variance in DBP (Table S8). These variances are within the ranges noted, lending credibility to 
the results from other studies. Note that both known and newly identified variants (with their 
interactions) explain some of the BP variance across ancestry groups.  
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Functional annotation and eQTL evidence 
 
For all 81 index variants representing the newly identified loci, we obtained functional 
annotations using HaploReg38 and RegulomeDB.39 There were 2 coding variants (1 missense and 
1 synonymous). Of the remaining non-coding variants (29 intronic and 52 intergenic), 17 are 
located in promoter histone marks, 53 in enhancer histone marks, 29 in DNase I marks, and 10 
altered the binding sites of regulatory proteins (Table S12). Conserved among vertebrates were 6 
variants as identified via GERP40 and 5 variants via SiPhy.41 RegulomeDB assigned class 1f 
(strong evidence for enhancer function) for 2 variants (Table S12), each of which likely affects 
the binding of regulatory elements and is linked to expression of a gene target. Of these, 
rs12741980 (locus 2, Table 4) is near the well-known BP locus MTHFR-NPPB-CLCN6 and a 
cis-acting expression quantitative trait locus (eQTL) for NPPA-AS1, which is expressed in 
multiple tissues, including thyroid and whole blood. Also, newly identified variant rs180940 
(locus 10, Table 4), with RegulomeDB score of 1f, is a cis-eQTL for the known locus ADRB1, 
an adrenergic receptor that mediates effects of the hormone epinephrine and the neurotransmitter 
norepinephrine,42 although it is about 80 kb upstream from this locus.  Of note, our results 
identified this known BP locus (rs2782980, P = 1.1×10-21 and rs1801253, P = 1.3×10-22, in Table 
S11).   
 
Among the 81 newly identified index variants, cis-eQTL evidence was available for 39 variants 
with varying degrees of association with expression probes (Table S12). In particular, 21 of 
them were identified by GTEx34 as cis-eQTLs across various tissues (Table S13). However, 
most of them are for cis-eQTLs that differ from their nearest assigned genes. For example, an 
intronic variant in WNT2B (rs351364) is a cis-eQTL for RHOC, which serves as a microtubule-
dependent signal that is required for the myosin contractile ring formation during cell cycle 
cytokinesis. Additionally, 11 variants (including rs7823056 in Figure 2) on chromosome 8 are 
cis-eQTLs for PRAG1, which is expressed in multiple tissues including the cerebellum and 
thyroid. The most abundant evidence of cis-eQTL association (with 44 eQTL hits from multiple 
studies) was observed for rs2243873, a intronic variant of EHMT2; it is predicted to regulate 
expression of many genes including HLA-C, HLA-B and HLA-DRB1 across multiple tissues. 
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The majority of the available data on tissue expression is derived from studies with a breadth of 
tissue types but with small sample sizes that limit the statistical power to detect association. A 
more in-depth but single-tissue functional annotation, reporting both cis- and trans-acting 
elements, was recently performed using microarray-based gene and exon expression levels in 
whole blood from over 5,000 individuals of the Framingham Heart Study.35 In this database, a 
total of 170 variant-transcript pairs (representing 36 variants) were significant at false discovery 
rate (FDR) < 0.05 (Table S14). There were 113 pairs for cis-eQTL, 3 pairs for trans-eQTL, and 
54 pairs for long-range cis-eQTL where the variant is located over 1 Mb away from the target 
transcript on the same chromosome. Among 36 variants, 9 variants were eQTLs for more than 5 
gene transcripts. For example, the 4 SNPs with the most significant eQTL evidence were 
rs2243873 (described in the previous paragraph), rs2071550, rs7823056, and rs13271489 (Locus 
8 in Table 2 and Figure 2) associated with 29, 12, 11, and 10 transcripts, respectively. 
Pathway and gene set enrichment analysis 
 
In order to distinguish between functional properties of loci with SBP compared to DBP effects, 
as well as between European-specific and trans-ancestry mechanisms, we conducted gene 
prioritization, gene set enrichment and tissue enrichment analyses using DEPICT43 separately by 
the four combinations of ancestry (EUR vs trans-ancestry) and BP trait (DBP vs SBP, Methods, 
Tables S15-S20). DEPICT significantly prioritized genes (FDR < 5%) at 12 European DBP loci, 
26 European SBP loci, 34 trans-ancestry DBP loci and 27 trans-ancestry SBP loci (Tables S15-
S19). In 43 cases, the prioritized gene for a specific locus differed from the nearest gene of the 
lead variant. Our DEPICT gene-set enrichment analyses highlighted a role for the identified 
variants in the cardiovascular system – predominantly affecting blood vessel biology (FDR < 
0.05 for a total of 134 gene-sets across the four analyses, Table S20).  
 
To identify connected gene sets and pathways implicated by our findings, we performed 
GeneGO analysis and text data mining using Literature Lab.36 The genes near our findings were 
enriched by GeneGO disease class “Chronic Kidney Failure” (P = 9.2×10-6). These same genes 
were also included in the much larger network representing the GeneGO disease class “Fibrosis” 
(P = 3.39×10-7) suggesting that genetic contribution of chronic kidney disease to BP is likely 
mediated by fibrosis. With Literature Lab, for the “Diseases” medical subject heading (MeSH), 
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Hypertension was strongly enriched (P = 0.0011), with contributions from ACE (93.4%), 
MTHFR (2.12%), ATP2B1 (1.18%), NPPB (0.54%), SH2B3 (0.43%), and SLC4A7 (0.13%). For 
the “Physiology” MeSH, blood pressure and cardiovascular physiological phenomena were 
enriched. Blood pressure (P = 0.0026) had contributions from ACE (96.77%), ATP2B1 (1.16%), 
NPPB (0.6%), MTHFR (0.46%), SH2B3 (0.46%), and FTO (0.3%); Cardiovascular physiological 
phenomena (P = 0.0056) had contributions from ACE (97.89%), NPPB (1%), ATP2B1 (0.37%), 
MTHFR (0.2%), SH2B3 (0.16%), TNFSF12 (0.09%), and AP5B1 (0.05%).  
Associations of BP loci with cardiometabolic traits 
 
To test association of all 81 newly identified BP-associated index variants with other 
cardiometabolic traits, we obtained lookup results for coronary artery disease (CAD), stroke, and 
other cardiometabolic traits related to adiposity, diabetes, and renal function (Tables S21-S27). 
We found that several of our newly identified index variants corroborate those previously 
associated with these cardiometabolic traits. To quantify this, we counted the number of variants 
that show association with p-value < 0.05 (highlighted in red). In the vast majority of cases (39 
out of 47, PBinomial=2.8 x 10-6), the observed count is higher than that expected by chance alone 
(Table S27). For example, we observed 9 and 14 such associations with CAD and myocardial 
infarction, respectively, where the expected count is 2.6 for both traits. This is consistent with the 
known association of increased BP with CAD mortality, independent of other risk factors.44 
Likewise, overlapping signals with other cardiometabolic traits, including those related to 
adiposity, diabetes, and renal function, support the notion that these traits share a common 
pathophysiology. For many of the obesity-related trait associations found in the GIANT 
Consortium, the genetic effects was influenced by adjustment and/or stratification by smoking 
status45 (Table S26).    
We also found corroborating evidence for some well-known loci associated with the renin-
angiotensin-aldosterone system (RAAS), including NPPA, NPPB, and SLC17A1-4 (Tables 2-4).4 
Variants in and near these loci have also been associated with CAD-related traits (NPPA/NPPB; 
Table S21), stroke (NPPA/NPPB, and SLC17A1-4; Table S22), obesity-related traits 
(NPPA/NPPB, and SLC17A1-4; Table S23), and diabetes-related traits (SLC17A1-4; Table S24) 
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The confluence of these data provide further evidence of the biologic relevance of these loci to 
BP regulation and the shared pathophysiology among cardiometabolic traits. 
Biological relevance of newly identified variants associated with BP 
 
Ciliopathies: Cilia are cellular protuberances found in several tissues including the kidney and 
brain that serve several purposes including cellular structure, growth, mobility, secretion, and 
environmental response.  New BP candidate genes SDCCAG8 (locus zoom plot in Figure 2), 
RPGRIP1L, and TMEM231 encode products that play critical roles in the structure and function 
of primary cilia including microtubules, basal bodies, and centrosomes. Mutations in these genes 
can lead to nephronophthisis-related ciliopathy, a monogenic cause of end-stage renal disease. 
DPYSL2, which encodes a microtubule assembly protein, has also been implicated in polycystic 
kidney disease.46 Cilia also contain actin fibers with motor proteins (dynein and kinesin) 
responsible for the transport of mitochondria and other cargo. DYNC2LI1 is another dynein-
associated protein associated with BP; dynein proteins co-localize in the kidney with the water 
channel aquaporin-2.47  
 
Telomere Maintenance: Since telomere length shortens with successive cell divisions, it has 
been proposed as a reflection of biologic age.48 Several genes with significant association with 
BP have roles in telomere maintenance including TNKS, PINX1, AKTIP (Tables 2-4), and 
TERF2IP. TNKS, which is in a locus previously associated with stroke-, obesity-, and diabetes-
related traits in other studies (Tables S22-S24), plays a role in the insulin-stimulated 
translocation of GLUT4 (glucose transporter) to the plasma membrane,49 and has additionally 
been associated with cardiovascular disease (CVD) risk and the inflammatory biomarker, C-
reactive protein.50 PINX1 has been previously associated with CVD,51 carotid artery intima-
media thickness,52 and serum triglyceride levels,53 and has also been associated with obesity- and 
diabetes-related traits (Tables S23-S24). AKTIP has been previously associated with stroke-
related traits in other studies (Table S22). Of note, the association at TNKS, PINX1, and AKTIP 
with multiple adiposity traits in the GIANT Consortium were strengthened by adjustment for 
smoking status (Table S26). TERF2IP has also been associated with stroke risk50 and coronary 
artery disease traits (Tables S21-S22).  
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Central Dopaminergic Signaling: Dopaminergic signaling in the kidney is known to modulate 
the secretion of renin54 and other key regulators of salt-water balance.55 There is evidence that 
central dopamine signaling also modulates BP via mechanisms that are independent of changes 
in sodium excretion.56 Early stages of Parkinson’s disease, a neurodegenerative disorder 
characterized by the loss of dopamine-secreting neurons, is characterized by autonomic 
dysfunction and BP dysregulation.57 In the current study, genes involved in central dopamine 
signaling were associated with BP, including MSRA and EBF2, which promote the survival and 
development of dopaminergic neurons, and GPR19,  a G-protein coupled receptor for the 
dopamine D2 receptor. MSRA has been previously associated with body mass index after 
adjustment with smoking status in the GIANT Consortium (Table S26) and GPR19 with renal 
function (Table S25) in the COGENT-Kidney Consortium.  
 
Modulators of vascular structure and function: CDKN1B, BCAR1-CFDP1, PXDN, and EEA1 
are involved in pathways that contribute to angiotensin II-induced vascular hypertrophy. 
Notably, the association of PXDN and EEA1 with BP is limited to AFR. CDKN1B has been 
previously associated with renal function (Table S25). BCAR1-CFDP1 has furthermore been 
identified as a genome-wide significant locus for carotid artery intima-media thickness and 
coronary artery disease risk (also Table S21);58 a potential causal variant in a BCAR1 regulatory 
domain has been identified.59 KCNG3 and KCNE4 are subunit modifiers of voltage-gated 
potassium channels expressed in vascular smooth muscle cells; activation of these channels leads 
to vasodilation. AVPR1A, which was associated with BP in AFR only, is a receptor for the 
vasoconstrictor vasopressin; murine knock-out models are hypotensive with impaired 
baroreceptor reflexes.60 
Discussion 
 
This is a large-scale multi-ancestry study to systematically use GxE interactions for identifying 
novel trait loci and for evaluating the role of GxE interactions in cardiovascular traits. In Stage 1, 
we performed a genome-wide analysis of gene-smoking interactions in 129,913 individuals 
across four ancestry groups using 1000 Genomes-imputed data, with follow up analysis in Stage 
2 of a small set of promising variants in 480,178 additional individuals across five ancestry 
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groups. We identified 40 known BP loci at genome-wide significance level (P < 5 × 10-8) in 
Stage 1 as well as 15 novel loci that are genome-wide significant in Stage 1 and replicated in 
Stage 2 using Bonferroni correction. A combined meta-analysis of Stages 1 and 2 results yielded 
16 additional known BP loci and 66 additional genome-wide significant loci (P < 5 × 10-8); 13, 
35, and 18 loci were identified in European, African and trans-ancestry, respectively. These 66 
additional loci were validated with  low false discovery rate (FDR q value < 0.1) (e.g., see 
Nelson et al.61). 
 
Identification of novel loci in this GxE analysis demonstrates the importance of incorporating 
environmental exposures in association discovery. Our newly identified loci including 
interactions with smoking collectively explained up to 1.7% additional variance in BP (beyond 
that explained by known BP variants) in several European cohorts. Furthermore, it may be 
particularly striking that our analyses also identified VAMP2, a component of the renin-
angiotensin-aldosterone system (RAAS), as a likely mediator of hypertension. VAMP2 
modulates cAMP-stimulated renin release by renal juxtaglomerular cells62 but has not been 
previously identified, even though other components of RAAS including NPPA, NPPB, and 
SLC17A1-4 have been found in previous GWAS and, indeed, among the 56 known BP loci 
identified in our study4; 63-65 
 
Several of our newly identified BP loci show evidence for shared pathophysiology with 
cardiometabolic traits. This is encouraging as hypertension is a frequent comorbidity of a variety 
of cardiometabolic traits, including dyslipidemia, type 2 diabetes, obesity and other disorders of 
substrate metabolism and storage. XKR6-MIR598 and MFHAS1 have been associated with serum 
triglyceride levels.66 LRP667; 68 and PPP1R3B69 have been associated with serum low-density 
lipoprotein levels and the metabolic syndrome. MSRA70 and SERTAD271 (associated in AFR) 
have been associated with obesity-related traits and adipocyte function, and PPP1R3B has been 
associated with steatohepatitis.72 We also identified the well-known obesity/diabetes locus 
FTO73; 74 as a newly identified BP locus (Figure 2). In addition to a recent discovery of the effect 
of an FTO variant on IRX3 and IRX5,75 variants in intron 1 of FTO have been identified that 
regulate the expression of nearby RPGRIP1L,74 shown to modulate leptin receptor trafficking 
and signaling in the hypothalamus.76 Variants in and near XKR6-MIR598, MFHAS1, MSRA, and 
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FTO have been associated with obesity- and diabetes-related traits in other studies (Tables S23-
S24). Among other variants in genes related to cardiometabolic traits, VAMP2 plays a role in the 
trafficking of the GLUT4 glucose receptor to the adipocyte plasma membrane.77 Finally, we 
identified a SNP (in AFR) in FABP3, a gene known to regulate mitochondrial β-oxidation.78 
Studies have shown that serum FABP3 transcript and protein levels are elevated in animal 
models and humans with hypertension compared with normotensive controls.79; 80 Consistent 
with a recent paper,6 our findings provide additional BP variants overlapping with metabolic trait 
loci.  
 
Some of the newly identified BP loci have been previously reported as suggestive (but not 
genome-wide significant) for smoking and other addiction traits. Among our newly identified 
loci, FTO, DPYSL2-ADRA1A, AJAP1, and SERINC2 have shown suggestive evidence of 
association with smoking-related traits,81; 82 illicit drug use,83 and alcohol consumption and 
dependence.84; 85 In addition, dopaminergic signaling has been implicated in addictive 
behaviors.86 Moreover, located in an intron of TNFSF12 (tumor necrosis factor superfamily 
member), our newly identified variant rs9899183 has many compelling regulatory features 
supporting its candidacy (Table S12); it resides in a region characterized by promoter histone 
marks in 23 tissues, in enhancer histone marks in 7 tissues, and by DNAse marks in 12 tissues. 
This variant is also identified as an eQTL for genes TNFSF12, CHRNB1 and SAT2; CHRNB1 (1 
nicotinic acetylcholine receptor subunit) may also contribute to nicotine dependence.87  
 
BP regulation critically involves both central and peripheral regulation via neuroendocrine and 
hormonal regulation in a complex integrated system that includes the brain, kidneys, adrenal 
glands, and vasculature. In addition to validating loci known for their involvement in the RAAS 
system, natriuretic peptide signaling, solute channels, and adrenergic and cholinergic receptor 
signaling (among others), we identified variants in or near new biological candidates for BP 
regulation. For example, several of our newly identified loci identified genes that have been 
previously implicated in monogenic causes of ciliopathy (nephronophthisis-related ciliopathy), a 
cause of end-stage renal disease in children and young adults.88; 89 This condition is a genetically 
heterogeneous autosomal recessive disease, and heterozygote siblings and other adults with 
incompletely penetrant versions of this disease may have variable degrees of hypertension, renal 
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insufficiency, obesity, and diabetes.90 Newly identified loci also include genes involved in 
dopaminergic signaling which may act both centrally and in the kidney to modulate BP 
regulation. Still other newly identified loci reside in or near genes involved in telomere 
maintenance. 
 
Of the 81 newly identified loci, 10 show genome-wide significant interactions although none 
were  replicated in Stage 2. Nine were identified with current smoking status. The ever smoking 
status is more heterogeneous since the effect of (former) smoking on BP decays over time from 
cessation.91 It is therefore not surprising that the analyses with the more homogeneous current 
smoking (CurSmk) status yielded larger (and more robust) effects on BP than did analyses using 
ever smoker (EverSmk) status.  Although the joint 2 df test succeeded in identifying 71 of the 81 
newly identified loci, the precise role of interaction is unclear. It is sobering to note that, 
although gene-smoking interactions may have helped identify a reasonably large number of the 
newly identified loci, the sample size we used here for genome-wide analysis in Stage 1 appears 
inadequate for identifying a large number of interaction effects (should they exist) through the 1 
DF interaction test alone. This may be because, if the pathobiology of BP involves large numbers 
of interactions, the majority of the interaction effects are likely (relatively) small enough whose 
identification requires the 2 DF joint test and/or require much larger sample sizes for identifying 
them through the 1 DF interaction test. Moreover, smoking is only one of many lifestyle 
attributes that may have interaction effects on BP.12 It is possible that some interactions we 
report here are driven by other lifestyle factors that may be correlated with smoking. A follow up 
study (such as Young et al92 and Tyrrell et al93) that jointly examines multiple lifestyle factors 
can shed light on further understanding of interaction effects on BP. 
 
Several large consortia-based BP GWAS papers have been published in recent years, 
dramatically increasing the number of BP loci. We treated 158 as known BP loci, which included 
the 71 loci that were reported by three recent papers.5-7 Of the 56 known BP loci we identified, 8 
overlap with these newly identified 71 loci. Hoffmann et al94 reported 75 novel loci (and 241 
additional loci not validated) based on > 300,000 individuals. The use of repeated measurements, 
beside the large sample size, appears to be responsible for the large number of novel loci 
discovered. Their study demonstrates the power of large sample sizes and repeated 
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measurements. Warren et al95 reported 107 validated loci. As shown in Table S28 in detail, nine 
of our newly identified loci include variants reported by these two papers.94; 95  Based on African 
ancestry, Liang et al reported 3 validated BP loci,96 one of which overlaps with our newly 
identified loci. 
 
Thirty-five loci were identified in African ancestry meta-analyses. As previous discoveries of BP 
loci were mostly in European ancestry, some using very large sample sizes, it may be harder to 
detect newly identified signals in European ancestry in our study. There are also more 
opportunities to identify lower frequency variants in African ancestry meta-analysis because 
there are more of these variants in this genetically more diverse population. However, because of 
the highly limited sample sizes available for African ancestry in Stage 2, genome-wide 
significant loci in Stage 1 African ancestry could not be formally replicated in Stage 2. 
Nevertheless, there is evidence supporting the validity of many of the African-specific newly 
identified loci: African-specific QQ plots were very similar with and without the known BP loci 
(Figure S10; Figure S12). Genomic control values are all close to 1, and the top signals are 
away from the expected null line in the QQ plots, suggesting that these may be real associations. 
Forest plots at the African-specific loci (Figure S13) were not heterogeneous across cohorts. For 
most loci, there exists at least one non-African ancestry showing effects in the same direction as 
those in African ancestry. They may also relate at least in part to unique smoking behaviors or 
BP regulation or both in African ancestry. However, these African-specific loci require further 
validation. 
 
There are several limitations in this large-scale multi-ancestry genome-wide investigation 
incorporating gene-smoking interactions. First, main effect only analysis without regard to 
smoking was not performed, and this limits our ability to resolve if any of our loci newly 
identified through the 2DF joint test could be found without smoking or gene-smoking 
interaction in the model. Second, although the strategy of clumping with a stringent LD threshold 
(r2 > 0.1) in addition to large physical distance threshold (± 1 Mb) is reasonable for inferring 
independent loci, conditional analysis of summary statistics from interaction analysis (similar to 
GCTA) would be more rigorous; however, such methods do not exist currently. Third, the 
relatively smaller stage 2 sample sizes available in African and Hispanic ancestries limit our 
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ability to formally replicate the loci that were newly identified in Stage 1 in those ancestries 
(including the 10 interactions). Fourth, power for novel discovery using interactions may be 
limited even in this reasonably large sample size. Fifth, if there is a G-C correlation, a potential 
confounding of GxE with interaction between covariate and smoking exposure (CxE) may exist, 
which can inflate Type I error of the GxE interaction test;97; 98 using a stratified model may help 
overcome such confounding. Sixth, our use of the fixed effect meta-analysis for trans-ancestry 
analysis may have limited the power in the presence of heterogeneous effects across ancestries; 
however, specialized trans-ancestry methods for GxE interactions do not exist. Seventh, subjects 
were grouped into each ancestry based on self-reported information instead of genetically 
computed ancestry. Finally,  the use of multiple hypothesis tests, multiple phenotypes and 
exposures, and multiple ancestries may contribute to inflation at some level. Striking a balance 
between false positives and false negatives, especially in the context of interactions, remains a 
challenge.  
 
In summary, our study identified a total of 137 genome-wide significant loci; 56 known loci, 15 
new loci identified in Stage 1 and formally replicated in Stage 2, and 66 additional BP loci 
identified through the combined analysis of Stages 1 and 2 and validated through low FDR. Our 
ability to identify this many loci is likely due to four factors: focus on gene-smoking interactions, 
consideration of multiple ancestries, the large aggregate sample sizes available, and the densely-
imputed data using the recent 1000 Genomes Project reference panel in Stage 1 analysis. The 10 
newly identified loci with significant interactions showed larger effects on BP in smokers. 
Thirty-five (35)  loci were identified only in African ancestry, highlighting the importance of 
pursuing genetic studies in diverse populations. In addition to evidence for shared 
pathophysiology with cardiometabolic traits, smoking and other addiction traits, our results 
provide compelling evidence for biological candidates for BP regulation such as modulators of 
vascular structure and function, ciliopathies, telomere maintenance, and central dopaminergic 
signaling. Our findings demonstrate how the interplay between genes and environment can help 
identify novel loci, open up new avenues for investigation about BP homeostasis, and highlight 
the promise of gene-lifestyle interactions for more in-depth genetic and environmental dissection 
of BP and other complex traits.
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Supplemental Data 
 
Supplemental Data include 5 Supplemental Notes, 17 figures, and 28 tables, all of which can be 
found  in online.  
URLs 
DEPICT, https://data.broadinstitute.org/mpg/depict/; dbSNP, ncbi.nlm.nih.gov/snp/; GeneGo, 
http://lsresearch.thomsonreuters.com/; GSEA, 
http://software.broadinstitute.org/gsea/msigdb/annotate.jsp; GTEx, gtextportal.org; Literature 
Lab, http://www.acumenta.com/acumenta/overview/index.php; LocusZoom, 
http://locuszoom.sph.umich.edu/; HaploReg, 
http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php; National Human Genome 
Research Institute (NHGRI) GWAS catalog, http://www.genome.gov/gwastudies/; NCBI Entrez 
gene, ncbi.nlm.nih.gov/gene/;  METAL, 
http://genome.sph.umich.edu/wiki/METAL_Documentation; RegulomeDB, 
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Figure legends 
 
Figure 1.  Study design and overall workflow. Stage 1 analysis identified 74 significant novel 
loci of which 15 were replicated in Stage 2. Replication in Stage 2 was hampered by limited 
sample sizes for African and Hispanic ancestries. Combined analysis leverages the full power of 
Stages 1 and 2, identifying 66 additional BP loci missed by the 2-step approach which were 
validated by FDR. Association analyses were performed for each of SBP and DBP, accounting 
for two smoking exposure variables, ‘current smoking’ status (CurSmk) and ‘ever smoking’ 
status (EverSmk). For each ancestry, cohort-specific results were combined to perform the 1 
degree of freedom (DF) test of the interaction effect and the 2 DF joint test of genetic main and 
interaction effects.  
 
Figure 2. Forest plots and LocusZoom plots for 3 newly identified loci (selected from Table 2) 
A-B: Variant rs7823056 and 10 additional variants on chromosome 8 are an eQTL for PRAG1, 
which is expressed in multiple tissues including the cerebellum and thyroid. 
C-D: Variant rs13271489 is a cis-eQTL for MSRA and predicted to modify enhancers in brain 
cells. MSRA has been shown to be associated with obesity-related traits and adipocyte function; 
it also promotes the survival and development of dopaminergic neurons .  
E-F: Variant rs11642015 is intronic to the well-known obesity/diabetes locus FTO. In addition, 
AKTIP in this locus has role in telomere maintenance . 
 
Figure 3. Scatter-plots of smoking-specific genetic effect sizes for BP traits at the 15 newly 
identified and 66 putative index variants listed in Tables 2-5.  The red points show variants with 
1 DF interaction P < 5×10-8 (1=rs12135881; 2=rs115234772; 3=rs62319742; 4=rs148387718; 
5=rs74701635; 6=rs150155092; 7=rs148772934; 8=rs138973557; 9=rs115893283; 
10=rs148753653). The blue points show variants with 1 DF interaction P < 1×10-5 
(11=rs11809589; 12=rs10166552; 13=rs11931572; 14=rs9348895; 15=rs76726877; 
16=rs61935525; 17=rs9965695; 18=rs10405764). 
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Tables 
 
Table 1. Basic characteristics of cohorts in Stages 1 and 2 in each ancestry  
 
Current Smoker Former Smoker Never Smoker % 
Male 
%  
HT 
% HT 
Meds 
Age  SBP  DBP  
Stage 1 N % N % N % Mean SD Mean SD Mean SD 
EUR 14,607 18.1 28,409 35.3 37,535 46.6 32.6 38.2 25.4 54.63 8.0 129.31 19.2 77.29 11.2 
AFR 5,545 21.5 7,185 27.8 13,121 50.8 26.5 55.9 39.5 54.49 9.1 136.39 22.8 81.75 12.8 
ASN 2,465 18.3 1,677 12.5 9,296 69.2 51.2 46.9 27.0 55.42 9.7 137.29 21.5 79.41 11.1 
HIS 1,068 12.1 2,160 24.5 5,577 63.3 24.9 43.5 13.3 55.50 11.0 130.50 22.0 76.95 11.8 
Stage 1 Total 23,685 18.4 39,431 30.7 65,529 50.9 32.8 43.1 27.7 54.74 8.6 131.69 20.4 78.42 11.6 
Stage 2 N % N % N % 
% 
Male 
%  
HT 
% HT 
Meds 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
Mean 
 
SD 
EUR 48,198 17.0 89,597 31.6 145,914 51.4 47.8 44.8 25.0 55.91 8.6 139.02 20.4 83.76 11.5 
AFR 1,971 29.8 1,579 23.8 3,075 46.4 40.9 54.3 42.8 53.66 10.2 137.00 21.6 83.32 12.8 
ASN 29,485 19.8 40,850 27.4 78,597 52.8 54.9 50.3 33.1 60.76 12.3 134.92 20.2 80.01 12.3 
HIS 2,739 20.3 2,559 18.9 8,231 60.8 41.0 26.9 16.3 45.86 13.8 124.08 20.0 75.09 11.9 
BRZ 998 22.6 514 11.6 2,902 65.8 48.0 15.5 6.3 27.78 3.2 119.91 16.0 74.68 11.5 
Stage 2 Total 83,391 18.2 135,099 29.6 238,719 52.2 49.7 45.9 27.4 56.84 9.9 137.12 20.3 82.26 11.8 
TOTAL 107,076 18.3 174,530 29.8 304,248 51.9 46.1 45.3 27.4 56.40 9.6 135.96 20.3 81.44 11.7 
The cell entries for the covariates and BP traits correspond to sample-size weighted averages across all cohorts in each category. 
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Table 2. Newly identified loci that are significant in Stage 1 and formally replicated in Stage 2.  
Locusa Nearest Genesb rsID Chr:Posc EA EAF Ancestry & Trait Stage 
Genetic 
Main 
Effect  
Estd 
Genetic 
Main 
Effect 
SEd 
Interaction 
Effect Estd 
Interaction 
Effect SEd 
2 DF Joint 
P-valuee 
1 MTHFR;CLCN6;NPPA rs202071545 1:11878161 d 0.945 ALL.SBP 1 1.24 0.28 -0.16 0.38 3.77×10-8 
       2 0.88 0.17 0.01 0.25 7.44×10-12 
       1+2 0.99 0.14 -0.04 0.20 9.39×10-20 
2 CLCN6;NPPA;NPPB rs3753581 1:11920189 a 0.327 ALL.SBP 1 -0.63 0.09 0.16 0.21 4.34×10-12 
       2 -0.43 0.05 0.00 0.11 5.52×10-23 
       1+2 -0.48 0.04 0.04 0.10 1.31×10-34 
3 NPPA;NPPB rs72640287 1:11965792 t 0.039 EUR.SBP 1 -2.05 0.43 -0.04 0.59 1.59×10-10 
       2 -0.86 0.19 -0.33 0.28 8.19×10-13 
       1+2 -1.06 0.18 -0.31 0.25 2.79×10-21 
4 WNT2B rs351364 1:113045061 a 0.297 ALL.SBP 1 -0.60 0.10 0.53 0.22 1.67×10-8 
       2 -0.42 0.05 0.14 0.11 5.38×10-19 
       1+2 -0.45 0.04 0.22 0.10 1.20×10-26 
5f CEP170;SDCCAG8;AKT3 rs3897821 1:243420388 a 0.705 ALL.DBP 1 -0.35 0.06 0.20 0.13 2.49×10-9 
       2 -0.20 0.03 0.00 0.07 1.51×10-12 
       1+2 -0.23 0.03 0.05 0.06 1.67×10-20 
6f FER1L5 rs7599598 2:97351840 a 0.564 EUR.DBP 1 -0.30 0.06 -0.15 0.14 5.93×10-8 
       2 -0.16 0.03 0.02 0.08 4.10×10-7 
       1+2 -0.19 0.03 -0.03 0.07 4.25×10-13 
7 SLC4A7 rs13063291 3:27446285 a 0.204 ALL.DBP 1 0.33 0.08 0.03 0.12 4.00×10-8 
       2 0.20 0.04 -0.14 0.06 3.75×10-6 
       1+2 0.23 0.04 -0.09 0.05 1.67×10-11 
8f PRAG1;MFHAS1 rs7823056 8:8382705 a 0.397 EUR.SBP 1 -0.56 0.10 -0.02 0.22 1.54×10-8 
       2 -0.42 0.05 0.16 0.13 1.55×10-14 
       1+2 -0.45 0.05 0.10 0.11 3.01×10-22 
9f PPP1R3B;TNKS rs62493780 8:9151051 t 0.238 EUR.SBP 1 0.89 0.18 -0.19 0.25 3.47×10-8 
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       2 0.46 0.09 -0.27 0.13 2.37×10-7 
       1+2 0.54 0.08 -0.24 0.12 2.95×10-13 
10f MIR124-1;MSRA rs13271489 8:9803712 t 0.478 EUR.SBP 1 0.55 0.10 0.02 0.22 6.37×10-8 
       2 0.44 0.05 -0.13 0.14 9.35×10-16 
       1+2 0.46 0.05 -0.08 0.12 4.56×10-23 
11 TNNI2;LSP1;TNNT3 rs7483477 11:1920255 t 0.75 ALL.SBP 1 -0.65 0.11 0.17 0.27 2.25×10-8 
       2 -0.36 0.05 0.08 0.12 1.77×10-13 
       1+2 -0.40 0.04 0.09 0.11 2.12×10-20 
12 POC1B;ATP2B1 rs7313874 12:89965049 t 0.325 ALL.SBP 1 -0.64 0.11 0.01 0.15 1.85×10-14 
       2 -0.48 0.06 -0.23 0.09 1.07×10-39 
       1+2 -0.52 0.05 -0.17 0.08 2.49×10-54 
13 ATP2B1 rs111337717 12:90037506 t 0.943 ALL.SBP 1 1.27 0.33 0.60 0.46 9.23×10-11 
       2 1.09 0.15 -0.26 0.22 2.86×10-18 
       1+2 1.13 0.13 -0.07 0.20 1.27×10-27 
14 PTPN11 rs7974266 12:113007602 t 0.513 ALL.DBP 1 0.19 0.13 0.57 0.18 3.58×10-8 
       2 0.23 0.06 0.19 0.09 6.50×10-12 
       1+2 0.22 0.06 0.28 0.08 5.91×10-19 
15f AKTIP;RPGRIP1L;FTO rs11642015 16:53802494 t 0.334 ALL.SBP 1 0.57 0.09 -0.19 0.21 2.78×10-9 
       2 0.29 0.05 0.08 0.11 6.74×10-13 
       1+2 0.35 0.04 0.03 0.10 9.91×10-21 
Each locus is genome-wide significant (P < 5×10-8) in Stage 1 and formally replicated in Stage 2 using Bonferroni-adjusted 
significance level (P < 0.05/74). Forest plots and LocusZoom plots are shown in Figures S3 and S4, respectively.  
aEach locus was determined through LD-based clumping, using ± 1 Mb around index variants, followed by LD threshold of r2 > 0.1; 
ancestry-specific LDs from 1000 Genomes Project were used when clumping within each ancestry and the entire cosmopolitan data 
were used for trans-ancestry clumping. 
bGene names were obtained using variant effect predictor (VEP) from Ensembl. Genes with intragenic index variants bolded. 
cPositions are based on build 37. 
dEffect is in mmHg unit. 
eThe most significant p-value (between 1 DF interaction test and 2 DF joint test) was set in bold. 
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fThese loci indicate completely novel loci, at least 1Mb away from any of known BP loci. 
BP: blood pressure. SBP: systolic BP. DBP: diastolic BP. EA: effect allele; EAF: effect allele frequency; 2 DF Joint P: P-value of the 
joint test with 2 degrees of freedom of genetic main and interaction effects. 1 DF Interaction P: P-value of the interaction test with 1 
degree of freedom; EUR: European ancestry. ALL: trans-ancestry (i.e., combining all ancestry groups through meta-analysis). 
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Table 3. Additional significant loci from the combined analyses of Stages 1 and 2 in trans-ancestry 
Locusa Nearest Genesb rsID Chr:Posc EA EAF 
Effectd P valuee 
Trait Genetic 
Main Interaction 
1 DF 
Interaction 2 DF Joint 
1 NPPA;NPPB rs12741980 1:11939593 a 0.943 0.68 0.02 0.852 3.04×10-14 SBP 
2f RSRC1 rs201851995 3:157837508 d 0.648 -0.6 0.38 0.0016 4.65×10-12 SBP 
3f INPP4B;GAB1 rs78763922 4:144054552 d 0.303 0.34 0.05 0.5067 4.03×10-13 SBP 
4 HOTTIP rs2023843 7:27243221 t 0.837 0.7 -0.2 0.1634 3.69×10-41 SBP 
5f MFHAS1;ERI1;PPP1R3B rs201133964 8:8607849 d 0.174 -0.52 -0.16 0.4366 1.24×10-9 SBP 
6f PPP1R3B;TNKS rs35904419 8:9376810 d 0.816 -0.19 -0.15 0.1761 1.34×10-8 DBP 
7 FAM167A-AS1;FAM167A;BLK rs4841531 8:11293390 t 0.161 -0.31 0.03 0.7825 1.32×10-8 SBP 
8f EBF2;LOC105379336; PPP2R2A;DPYSL2;ADRA1A rs58429174 8:26011922 t 0.262 -0.12 -0.14 0.026 2.60×10
-9 DBP 
9 ADRB1 rs180940 10:115722411 a 0.391 -0.19 0.06 0.1514 5.00×10-12 DBP 
10 AP5B1;OVOL1 rs201316070 11:65548558 d 0.061 -0.6 -0.23 0.462 1.54×10-9 SBP 
11f LRP6;GPR19;APOLD1;GPRC5A rs72656645 12:12881055 a 0.7 0.36 -0.13 0.064 4.49×10-15 SBP 
12 SLCO1C1;SLCO1B3; SLCO1B7;SLCO1B1 rs73073686 12:20354507 a 0.231 -0.24 -0.07 0.2553 1.68×10
-18 DBP 
13 ATP2B1 rs10858948 12:90478651 a 0.578 -0.18 0 0.6992 4.74×10-15 DBP 
14 MED13L rs11067762 12:116198214 a 0.176 -0.24 -0.05 0.1951 5.30×10-18 DBP 
15 CYP1A1-2;ULK3;SCAMP2;MPI rs10628234 15:75211142 d 0.3 0.32 -0.22 0.0253 1.57×10-24 DBP 
16f LDHD;CFDP1;TMEM231; TERF2IP rs4888411 16:75443183 a 0.56 0.26 0.12 0.0467 1.19×10-18 SBP 
17f SLC2A4;KCTD11;TNFSF12; TNFSF13;ATP1B2 rs9899183 17:7452977 t 0.742 -0.35 0.07 0.6683 1.24×10
-12 SBP 
18f ACE rs4968782 17:61548476 a 0.616 -0.2 0.08 0.2179 3.30×10-16 DBP 
Each locus is genome-wide significant (P < 5×10-8) in the combined analyses of Stages 1 and 2 and had FDR q value < 0.1. Forest 
plots and LocusZoom plots are shown in Figures S3 and S4, respectively.  
aEach locus was determined through LD-based clumping, using ± 1 Mb around index variants, followed by LD threshold of r2 > 0.1; 
ancestry-specific LDs from 1000 Genomes Project were used when clumping within each ancestry and the entire cosmopolitan data 
were used for trans-ancestry clumping. 
bGene names were obtained using variant effect predictor (VEP) from Ensembl. Genes with intragenic index variants bolded. 
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cPositions are based on build 37. 
dEffect is in mmHg unit. 
eThe most significant p-value (between 1 DF interaction test and 2 DF joint test) was set in bold. 
fThese loci indicate completely novel loci, at least 1Mb away from any of known BP loci. 
BP: blood pressure. SBP: systolic BP. DBP: diastolic BP. EA: effect allele; EAF: effect allele frequency; 2 DF Joint P: P-value of the 
joint test with 2 degrees of freedom of genetic main and interaction effects. 1 DF Interaction P: P-value of the interaction test with 1 
degree of freedom.  
 Page 43 of 57 
 
Table 4. Additional significant loci from the combined analyses of Stages 1 and 2 in European-ancestry 
Locusa Nearest Genesb rsID Chr:Posc EA EAF 
Effectd P valuee 
Trait Genetic 
Main Interaction 
1 DF 
Interaction 2 DF Joint 
1 MTHFR;CLCN6 rs6541006 1:11857526 a 0.071 -0.85 0 0.6454 3.17×10-19 SBP 
2f KCNG3;DYNC2LI1 rs73923009 2:43141074 a 0.099 -0.36 0.07 0.6165 1.21×10-14 DBP 
3 SLC17A1-4;HFE rs7753826 6:26042239 a 0.189 0.36 -0.05 0.4371 1.72×10-25 DBP 
4 SLC44A4;EHMT2; STK19;CYP21A2;TNXB rs2243873 6:31863433 a 0.556 0.45 -0.19 0.0472 3.33×10
-14 SBP 
5 SLC44A4;EHMT2; HLA-DQB2;STK19;CYP21A2;TNXB rs2071550 6:32730940 a 0.307 0.29 -0.22 0.0003 1.17×10
-9 DBP 
6f TNKS;MSRA rs4841235 8:9683358 a 0.426 0.37 -0.1 0.7078 4.78×10-15 SBP 
7 SOX7;PINX1 rs6995692 8:10587008 c 0.563 -0.44 0.31 0.0102 4.11×10-19 SBP 
8f ADARB2 rs150155092 10:1769881 d 0.013 4.76 -18.32 7.43×10-9 1.94×10-8 SBP 
9 KAT5;RNASEH2C rs72941051 11:65478893 t 0.074 -0.39 0.07 0.3701 1.75×10-11 DBP 
10f FAM19A2;AVPR1A rs17713040 12:62467714 t 0.977 0.24 0.31 0.7633 3.44×10-8 DBP 
11 FAM109A;SH2B3;ATXN2 rs4375492 12:111835990 a 0.794 0.35 0.03 0.8187 1.03×10-26 DBP 
12 MPI;COX5A;SCAMP5 rs12050494 15:75260896 a 0.316 0.32 -0.06 0.525 3.01×10-27 DBP 
13f NAA38;KCNAB3;VAMP2 rs74439044 17:7781019 t 0.903 -0.36 -0.14 0.1507 2.43×10-21 DBP 
Each locus is genome-wide significant (P < 5×10-8) in the combined analyses of Stages 1 and 2 and had FDR q value < 0.1. Forest 
plots and LocusZoom plots are shown in Figures S3 and S4, respectively.  
aEach locus was determined through LD-based clumping, using ± 1 Mb around index variants, followed by LD threshold of r2 > 0.1; 
ancestry-specific LDs from 1000 Genomes Project were used when clumping within each ancestry and the entire cosmopolitan data 
were used for trans-ancestry clumping.  
bGene names were obtained using variant effect predictor (VEP) from Ensembl. Genes with intragenic index variants bolded. 
cPositions are based on build 37. 
dEffect is in mmHg unit. 
eThe most significant p-value (between 1 DF interaction test and 2 DF joint test) was set in bold. 
fThese loci indicate completely novel loci, at least 1Mb away from any of known BP loci. 
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BP: blood pressure. SBP: systolic BP. DBP: diastolic BP. EA: effect allele; EAF: effect allele frequency; 2 DF Joint P: P-value of the 
joint test with 2 degrees of freedom of genetic main and interaction effects. 1 DF Interaction P: P-value of the interaction test with 1 
degree of freedom.  
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Table 5. Additional significant loci from the combined analyses of Stages 1 and 2 in African-ancestry 
Locusa Nearest Genesb rsID Chr:Posc EA EAF 
Effectd P valuee 
Trait Genetic 
Main Interaction 
1 DF 
Interaction 2 DF Joint 
1f AJAP1 rs12135881 1:4781922 c 0.988 -2.05 16.94 2.06×10-8 3.09×10-9 SBP 
2f FABP3;SERINC2;TINAGL1 rs11809589 1:31970118 a 0.012 -1.11 -18.04 1.54×10-7 7.71×10-10 SBP 
3f LOC101928219 rs182662555 1:96289336 t 0.988 6.15 -4.45 0.00201 1.79×10-8 DBP 
4f PXDN;MYT1L rs75247762 2:1893133 t 0.014 -2.37 -12.93 1.45×10-5 1.17×10-9 SBP 
5f ASB3;ERLEC1;GPR75 rs115234772 2:53650295 a 0.987 -0.1 8.5 2.13×10-9 1.07×10-11 DBP 
6f SERTAD2;SLC1A4 rs145162854 2:65104447 a 0.015 -3.17 -2.61 0.171 6.63×10-9 SBP 
7f ACOXL rs116008367 2:111807546 c 0.014 -0.86 -5.35 5.00×10-5 3.09×10-8 DBP 
8f KCNE4;SCG2 rs10166552 2:224036537 t 0.016 -0.15 -10.83 4.28×10-6 1.52×10-9 SBP 
9f TPRA1;MCM2 rs139963642 3:127314188 t 0.013 -6.35 1.23 0.6742 1.55×10-8 DBP 
10f PCDH7 rs11931572 4:30086104 a 0.968 -0.45 3.28 2.71×10-6 2.91×10-8 DBP 
11f SPRY1;LINC01091 rs62319742 4:124581262 a 0.014 1.98 -10.98 3.43×10-8 4.09×10-8 DBP 
12f HSD17B4 rs140543491 5:118923601 a 0.017 -3 -16.29 1.24×10-5 5.34×10-9 SBP 
13f OFCC1 rs148387718 6:9446000 t 0.014 0.59 -7.84 2.70×10-8 1.77×10-11 DBP 
14f NEDD9;LOC105374928 rs9348895 6:11496048 a 0.586 0.11 1.21 6.15×10-6 1.71×10-8 DBP 
15f MYO6;IMPG1 rs58806982 6:76688806 t 0.01 -11.24 14.92 1.47×10-5 4.57×10-8 SBP 
16f TARID;SLC2A12 rs76987554 6:134080855 t 0.062 -1.57 0 0.6676 1.63×10-8 SBP 
17f ARID1B rs112140754 6:157245233 t 0.988 0.97 7.6 0.00104 2.44×10-8 DBP 
18f BZW2 rs116196735 7:16710605 a 0.018 -2.88 -13.75 0.00037 6.98×10-10 SBP 
19f MED30;EXT1 rs74701635 8:118758316 t 0.016 3.79 -19.2 2.38×10-9 2.13×10-9 SBP 
20f ADAMTSL1;MIR3152 rs146250839 9:18189778 a 0.976 0.35 2.79 0.00029 4.36×10-8 DBP 
21f SPIN1;S1PR3;SHC3;CKS2 rs192642798 9:91503987 a 0.012 -8.38 3.95 0.346 4.23×10-9 SBP 
22f FZD8 rs76726877 10:36313497 t 0.015 -1.55 -9.14 4.17×10-6 4.47×10-10 DBP 
23f SFRP5;CRTAC1 rs11599481 10:99640463 t 0.058 -0.9 -3.33 1.38×10-5 4.55×10-11 SBP 
24f TSPAN18;PRDM11;SYT13 rs148772934 11:45005681 t 0.986 -0.57 11.66 1.00×10-8 1.20×10-9 DBP 
25 SLC15A3;CD6; LOC105369325; CD5 rs11601370 11:60834043 t 0.976 1.34 6.63 0.00867 3.01×10
-9 SBP 
26f LOC101928944 rs74601585 11:80140007 t 0.017 -3.93 -2.58 0.2715 8.06×10-9 SBP 
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27f LOC105369408 rs78103586 11:133893928 a 0.029 -1.65 -5.27 0.00163 2.26×10-9 DBP 
28f PLEKHG7;EEA1;LOC643339 rs61935525 12:93645481 c 0.985 1.26 10.15 3.28×10-7 3.28×10-11 DBP 
29f DICER1;CLMN rs187852559 14:95794914 a 0.013 -1.67 -4.93 0.0246 8.74×10-10 DBP 
30f SETD3;CCNK rs1257310 14:99810427 a 0.784 1.03 0.98 0.1335 1.67×10-8 SBP 
31 GPR139;GP2;UMOD;PDILT rs148753653 16:20230175 a 0.981 5.25 -9.4 1.89×10-8 6.30×10-8 DBP 
32f LOC339166;WSCD1 rs138973557 17:5699720 t 0.903 0.36 2.09 2.12×10-8 1.81×10-10 DBP 
33f DYM;LIPG;ACAA2;MYO5B rs9965695 18:47261614 t 0.982 0.29 13.32 8.36×10-6 1.63×10-8 SBP 
34f ZNF98 rs10405764 19:22598479 t 0.017 0.91 -19.1 2.13×10-7 4.30×10-8 SBP 
35f BMP7 rs115893283 20:55404165 t 0.042 0.9 -9.05 2.53×10-8 4.24×10-12 SBP 
Each locus is genome-wide significant (P < 5×10-8) in the combined analyses of Stages 1 and 2 and had FDR q value < 0.1. Forest 
plots and LocusZoom plots are shown in Figures S3 and S4, respectively.  
aEach locus was determined through LD-based clumping, using ± 1 Mb around index variants, followed by LD threshold of r2 > 0.1; 
ancestry-specific LDs from 1000 Genomes Project were used when clumping within each ancestry and the entire cosmopolitan data 
were used for trans-ancestry clumping. 
bGene names were obtained using variant effect predictor (VEP) from Ensembl. Genes with intragenic index variants bolded. 
cPositions are based on build 37. 
dEffect is in mmHg unit. 
eThe most significant p-value (between 1 DF interaction test and 2 DF joint test) was set in bold. 
fThese loci indicate completely novel loci, at least 1Mb away from any of known BP loci. 
 
BP: blood pressure. SBP: systolic BP. DBP: diastolic BP. EA: effect allele; EAF: effect allele frequency; 2 DF Joint P: P-value of the 
joint test with 2 degrees of freedom of genetic main and interaction effects. 1 DF Interaction P: P-value of the interaction test with 1 
degree of freedom.  
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